US FDA delays Nuvigil approval | 
US health regulators have delayed the decision whether to approve Nuvigil, Cephalon’s sleep disorder drug which seeks to treat jet lag.
Earlier last year, the US Food and Drug Administration (FDA) granted a priority review for Cephalon’s Nuvigil. However, the regulator also said that it needed more time to review the drug.
While Cephalon still does not have market approval, it is already being prescribed for patients that suffer from excessive sleepiness due to sleep apnea, narcolepsy, and shift work disorder.
You must be logged in to post a comment.
Latest Headlines
- CPAP treatment is best for elderly sleep apnea patients
- Sleep apnea awareness
- Obstructive sleep apnea linked to cancer growth in mice
- Sleep apnea linked to bedwetting
- Novel therapy improves cardiovascular health in central sleep apnea patients
- Sleep apnea: a growing health concern
- Sleep Apnea Patients Unable to Tolerate CPAP Or Any Device? – A New Conservative Hope Available Now
- Insomnia linked to high insulin resistance in diabetics
- Philips displays sleep therapy products in Dubai
- The risks of sleep apnea
- AZ-TMJ – Now Reaching Even More Patients with Their Effective Sleep Apnea Treatments
- Pro baseball player gets sidelined due to sleep disorder
- The CPAP Shop Introduces New FREE eBook For CPAP Machine Users
- Sleep loss leads to greater appetite
- Sleepless elites far from grumpy and tired
In The News
Sleep loss boosts optimism and limits negative thinking
New research is looking into the
New drug funding for narcoleptic New Zealanders
Pharmac, New Zealand’s only agency under
Sleeping on your side may help prevent snoring
According to scientists, there are two
Sleep patient dies during study
What was expected to be a